Japan first in the world to approve Dupixent (dupilumab) for chronic spontaneous urticaria (CSU) – Regeneron + Sanofi
Regeneron Pharmaceuticals, Inc. announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of… read more.
